Why It Matters
Susan G. Komen for the Cure filed a quarter two 2026 lobbying disclosure act filing showing the organization spent $130,000 on federal advocacy during the quarter. The nonprofit lobbying registration reflects ongoing efforts to shape cancer research funding and screening policies as Congress debates healthcare appropriations and disease detection programs.
By the Numbers
The $130,000 in quarter two 2026 advocacy spending represents a significant increase from the previous quarter. The organization reported $80,000 in lobbying disclosure act filing amounts for quarter one 2026.
Broader Context
The nonprofit political activity represents continued engagement on cancer research and screening matters that have been central to the organization's advocacy in recent years. Previous quarters show Komen has lobbied on multiple pieces of legislation, including bills addressing breast cancer diagnosis access, early detection screening coverage, and cancer research funding through appropriations measures.
Susan G. Komen's in-house lobbying team consists of Molly Guthrie, Vice President of Policy and Advocacy, and Valerie Nelson, Manager of Federal Policy and Advocacy.
The Bottom Line
Susan G. Komen's activity demonstrates sustained engagement in federal advocacy around cancer research and screening policy.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article